Videos |View More
First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.
With a focus on immunotherapy, CAR T-cell therapy and bispecific treatments, Dr. Niu believes a more direct, targeted approach will become the gold standard for leukemia and other diseases in the near future, offering patients a better quality of life.
Meet the Team: Dr. Brian Betts
How aggressive graft versus host disease prophylaxis, nuanced donor selection and other approaches have led to critical gains in survival and cure rate and facilitate a safe and earlier return home.
Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak
Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.
Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities
Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, presented research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...
News
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
A recent research effort spearheaded by experts at Roswell Park Comprehensive Cancer Center demonstrates a way to exploit drug side effects in order to prime tumors to support better responses to immunotherapy.
Clinical trials launched recently at Roswell Park Comprehensive Cancer Center — one exclusive to Roswell Park and the other offered at only eight sites nationwide — focus on new approaches.
This site is intended for healthcare professionals